Cancer & Metabolism

metrics 2024

Advancing Insights into Cancer's Metabolic Landscape

Introduction

Cancer & Metabolism is a distinguished open-access journal published by BMC, dedicated to advancing the understanding of the complex interactions between cancer biology and metabolic processes. Since its inception in 2013, it has provided a platform for researchers, clinicians, and students to disseminate groundbreaking research and innovative findings within the fields of oncology and metabolism. The journal, identified by its E-ISSN 2049-3002, is recognized for contributing valuable insights into metabolic alterations that influence cancer progression, treatment responses, and overall patient outcomes. With a firm commitment to open access, Cancer & Metabolism ensures that research is freely available to the global scientific community, fostering collaboration and accelerating discoveries that can lead to improved therapeutic strategies. As a vital resource in cancer research, this journal appeals to a broad audience, including researchers looking to share their latest findings, professionals seeking to stay informed on cutting-edge developments, and students eager to delve into the relationship between metabolism and cancer.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor6.00
Journal Impact Factor (5 years)5.40
H-Index-
Journal IF Without Self6.00
Eigen Factor0.00
Normal Eigen Factor0.33
Influence1.45
Immediacy Index0.70
Cited Half Life6.30
Citing Half Life6.30
JCI1.04
Total Documents-
WOS Total Citations1467
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

CELL BIOLOGY
Rank 51/205
Percentile 75.40
Quartile Q1
ONCOLOGY
Rank 51/322
Percentile 84.30
Quartile Q1

JCI (Web Of Science)

CELL BIOLOGY
Rank 55/205
Percentile 73.17
Quartile Q2
ONCOLOGY
Rank 74/322
Percentile 77.02
Quartile Q1

Quartile History

Similar Journals

Frontiers in Bioscience-Landmark

Exploring the Depths of Molecular Innovation
Publisher: IMR PRESSISSN: 2768-6701Frequency: 12 issues/year

Frontiers in Bioscience-Landmark is a prestigious journal published by IMR PRESS that focuses on a diverse array of topics within the fields of biochemistry, genetics, molecular biology, immunology, and microbiology. With the ISSN 2768-6701 and E-ISSN 2768-6698, this journal has carved a significant niche since its inception in 1996, making its mark in contributions to the scientific community all the way through to 2024. Having achieved a respectable Q2 cohort rank in multiple categories, including biochemistry and immunology, it stands out for its impactful research, evidenced by its current Scopus rankings which highlight it as a vital resource for ongoing studies and advancements in the biosciences. Despite not being open access, the journal ensures that readers have access to high-quality research articles that are peer-reviewed and designed to foster academic discourse. The importance of Frontiers in Bioscience-Landmark lies in its commitment to disseminating innovative findings that can significantly enhance our understanding of biological sciences, making it an essential read for researchers, professionals, and students alike.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Fostering collaboration for groundbreaking cancer discoveries.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

INTERNATIONAL JOURNAL OF ONCOLOGY

Advancing cancer research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Cell Communication and Signaling

Pioneering Research in Biochemical Pathways
Publisher: BMCISSN: Frequency: 1 issue/year

Cell Communication and Signaling is a premier peer-reviewed journal published by BMC that has made significant contributions to the fields of biochemistry, cell biology, and molecular biology since its establishment in 2003. As an open access journal, it offers unrestricted access to high-quality research, fostering collaboration and innovation among scientists around the globe. The journal is distinguished by its Q1 ranking in all three relevant categories for 2023, underscoring its critical role in advancing the understanding of cellular communication mechanisms and signaling pathways. Positioned within the United Kingdom, Cell Communication and Signaling has been an invaluable resource for researchers, professionals, and students alike, ensuring that the latest findings are accessible to a diverse range of audiences. With an impressive Scopus ranking—placing it in the top percentiles within its subject areas—this journal continues to set the standard for excellence in the pursuit of understanding complex cellular interactions.

Trends in Cancer

Advancing Cancer Research with Insightful Innovations
Publisher: CELL PRESSISSN: 2405-8025Frequency: 12 issues/year

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

CANCER AND METASTASIS REVIEWS

Exploring the Complexities of Cancer Progression
Publisher: SPRINGERISSN: 0167-7659Frequency: 4 issues/year

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Annual Review of Cancer Biology

Bridging Academia and Clinical Applications in Cancer Research
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

PPAR Research

Connecting Researchers with PPAR Insights
Publisher: HINDAWI LTDISSN: 1687-4757Frequency:

PPAR Research, an esteemed journal published by HINDAWI LTD, specializes in the rapidly evolving fields of drug discovery and pharmacology, contributing significantly to the body of research surrounding peroxisome proliferator-activated receptors (PPARs) and their roles in various biochemical processes. With an open access policy implemented since 2006, the journal ensures that its high-quality content is readily available, promoting widespread dissemination of knowledge. Currently ranked in the Q2 category for both Drug Discovery and Medical Pharmacology, it boasts a respectable position within the scientific community, evidenced by its Scopus rankings. PPAR Research serves as an essential resource for researchers, professionals, and students looking to advance their understanding of PPAR biology and its implications in therapeutic development. The journal's commitment to excellence and accessibility makes it a key player in supporting innovative research and critical discussions in the life sciences.

Cancer Drug Resistance

Unraveling the Mysteries of Drug Resistance in Cancer.
Publisher: OAE PUBLISHING INCISSN: Frequency: 1 issue/year

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

BIOCHEMICAL JOURNAL

Driving Scientific Excellence in Biochemistry
Publisher: PORTLAND PRESS LTDISSN: 0264-6021Frequency: 24 issues/year

BIOCHEMICAL JOURNAL, published by Portland Press Ltd, stands as a leading publication in the fields of Biochemistry, Cell Biology, and Molecular Biology, reflecting a commitment to advancing scientific knowledge since its inception in 1945. With a distinguished Q1 ranking across these categories and impressive Scopus rankings, the journal serves as an invaluable resource for researchers, professionals, and students alike, facilitating critical discoveries and innovative research practices. Although not currently offering open access, the journal provides a platform for high-quality peer-reviewed articles, ensuring rigorous standards in the dissemination of biochemical research. Spanning over seven decades and continuing through to 2024, the BIOCHEMICAL JOURNAL fosters an environment where cutting-edge biochemical research thrives, supporting the global scientific community's efforts to address complex biological questions and enhance our understanding of fundamental cellular processes.